| Bid | 3.2 |
| Market Cap | 2.34M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 5571.72 |
| PE Ratio (ttm) | 0 |
| Forward PE | n/a |
| Analyst | Strong Buy |
| Ask | 3.5 |
| Volume | 161,929 |
| Avg. Volume (20D) | 58,505 |
| Open | 3.50 |
| Previous Close | 3.18 |
| Day's Range | 3.15 - 3.50 |
| 52-Week Range | 2.66 - 152.79 |
| Beta | undefined |
About RNAZ
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inh...
Analyst Forecast
According to 1 analyst ratings, the average rating for RNAZ stock is "Strong Buy." The 12-month stock price forecast is $20, which is an increase of 496.20% from the latest price.
8 months ago · https://www.defenseworld.net
Q2 2024 EPS Estimates for TransCode Therapeutics, Inc. (NASDAQ:RNAZ) Decreased by AnalystTransCode Therapeutics, Inc. (NASDAQ:RNAZ – Free Report) – Equities research analysts at HC Wainwright reduced their Q2 2024 earnings per share estimates for shares of TransCode Therapeuti...
1 year ago · proactiveinvestors.com
Transcode Therapeutic stock whipsaws lower after cut price placingTransCode Therapeutics (NASDAQ:RNAZ) stock has seen a wild 24 hours of trading as the Boston headquartered nano-cap drug discovery firm rocketed Monday, before coming back down to earth with an after-...
1 year ago · proactiveinvestors.com
TransCode Therapeutics stock skyrockets on positive brain cancer trial resultsTransCode Therapeutics (NASDAQ:RNAZ) shares took off after it announced positive results from a study of its lead drug candidate TTX-MC138 in mice models bearing human glioblastoma multiforme (GBM) tu...
